Novo Nordisk's Victoza (liraglutide), the first glucagon-like peptide-1 receptor agonist subcutaneous injection, received FDA approval for the treatment of type 2 diabetes mellitus.
Laura Moretti Challen, PharmD, BCPS
Advertisement
Articles by Laura Moretti Challen, PharmD, BCPS
Onglyza (saxagliptin) comarketed by Bristol-Myers Squibb and AstraZeneca, is FDA-approved to improve glycemic control for the treatment of type 2 diabetes.
Advertisement
Latest Updated Articles
- Rx Product News Profile: A Closer Look at New FDA Actions: Novo Nordisk's Victoza
Published: June 15th 2010 | Updated:
- Rx Product News Profile: A Closer Look at New FDA Actions: Bristol-Myers Squibb's and AstraZeneca's Onglyza
Published: May 11th 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
2
Evolving Mortality Trends in Heart Failure and Vascular Disease: The Critical Role of Pharmacists in Addressing Cardiovascular Risk
3
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
4
SGLT2 Inhibitors Linked to Lower Atrial Fibrillation Risk, Recurrence
5
